anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tramadol hydrochloride and acetaminophen tablets combine two analgesics, tramadol 37.5 mg and acetaminophen 325 mg.

The chemical name for tramadol hydrochloride is (±)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. Its structural formula is:

The molecular weight of tramadol hydrochloride is 299.84. Tramadol hydrochloride is a white, bitter, crystalline and odorless powder.

The chemical name for acetaminophen is N-acetyl-p-aminophenol. Its structural formula is:

The molecular weight of acetaminophen is 151.16. Acetaminophen is an analgesic and antipyretic agent which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste.

Tramadol hydrochloride and acetaminophen tablets contain 37.5 mg tramadol hydrochloride and 325 mg acetaminophen and are beige in color. Inactive ingredients in the tablet are carnauba wax, crospovidone, microcrystalline cellulose, Opadry® beige, pregelatinized starch, povidone, sodium starch glycolate and stearic acid. Opadry Beige contains: iron oxide black, iron oxide red, iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
The invention concerns a sonosensitizing agent (ASS) based on zinc oxide (ZnO) micro- and/ or nanoparticles activated by external pressure stimuli, specifically by ultrasounds (US). The invention also concerns a method of ultrasonic activation of a solution to be treated with dispersed sonosensitizing agent (6). The invention also concerns an ultrasonic activation system (10) of a solution to be treated with dispersed sonosensitizing agent (6) by ultrasounds (US). The invention finds preferred and advantageous applications as a contrast medium to induce targeted cytotoxicity in target tumour cells. The most advantageous implementation provides for the use of the invention described in the Italian patent application no. 102017000129243 filed on November 13th, 2017 and titled "Nanocostrutto biomimetico non immunogenico per la terapia antitumorale" and in the corresponding international application published with no. WO 2019/092550 A1 on May 16th, 2019.
Participants randomized to this arm will receive tDCS at the right DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time.
AIM: Diminished hepatic insulin clearance (HIC) is observed in obese adults and is presumed to be mediated by fatty liver. However, few reports have examined HIC in Chinese children with metabolic (dysfunction)-associated fatty liver disease (MAFLD). This study aimed to investigate the correlation between HIC, insulin sensitivity and β-cell function in obese Chinese children with MAFLD.
METHODS: In total, 204 obese children (74 MAFLD) aged 4-17 years were enrolled into this study. HIC, insulin sensitivity and β-cell function were calculated using the oral glucose tolerance test (1.75 g/kg body weight). Correlation analyses between the HIC and clinical variables were performed using Pearson's product-moment correlation coefficients. HIC and glucose homeostasis were assessed in a high-fat diet mouse model, and liver samples were collected for molecular analysis.
RESULTS: Obese children with MAFLD exhibited significantly lower HIC (AUCC-peptide/insulin ratio, p = 0.0019), higher insulin resistance (homeostatic model assessment of insulin resistance, p = 0.002), and increased compensatory β-cell function (homeostatic model assessment-β, p = 0.046) than obese children without liver involvement. Notably, HIC was negatively correlated with insulin sensitivity (r = -0.5035, p < 0.0001) and β-cell function (r = -0.4576, p < 0.0001). However, pancreatic β-cell dysfunction (p = 0.046) was accompanied by future reduced HIC (p = 0.034) in children with MAFLD in prediabetes. In a high-fat diet mouse model, MAFLD mice showed a 50% reduction in insulin-degrading enzyme expression, consistent with the observed decrease in HIC.
CONCLUSIONS: A lower HIC may offload pancreatic β-cells at an early stage. However, obese children with MAFLD are at risk of developing diabetes, and preventive efforts should be prioritized.
"Severe acute respiratory syndrome" coronavirus 2 (SARS-Cov-2) is a new coronavirus that induces pneumonia called Corona Virus Disease- 19 (COVID-19), an infected 1.5 million people worldwide and caused the more than 85,000 patients died. COVID-19 usually comes in the form of viral pneumonia but with the peculiarities of a risk frequent worsening towards acute respiratory distress syndrome (ARDS) and a usual duration of oxygen dependence in fragile patients by their age or their comorbidities. To date, there is no therapy effective in preventing or treating COVID-19. Drug identification is a major concern and a public health emergency. Retrospective study (Wu 2020) highlighted improved survival in COVID-19 patients with acute ARDS and treated with corticosteroids (CS). So even in the absence of evidence of effectiveness, the SCs are used for COVID-19 oxygen-dependent patients or with an ARDS. However, their benefit / risk remains debated (Russel 2020). On histological samples of COVID-19, diffuse alveolar damage (DAD) has been especially observed (Hanley 2020). DAD is described histologically in an exudative phase, an organizational phase and a irreversible fibrotic phase (Hughes 2017). SC could have an effect beneficial by limiting the exudative / inflammatory phase but also that organization whose histological and CT aspects are sometimes indistinguishable from organized pneumonia, a form of pulmonary repair aberrant very corticosensitive (Travis 2013). Chest scans performed in the face of the persistence or worsening of oxygen dependence beyond the 7th day of COVID-19 symptoms, could help discern indirect complications (pulmonary embolism, exacerbation of COPD, bacterial superinfection, etc.) of an unfavorable course COVID-19 (by displaying an aspect suggesting DAD in particular during the organization phase). We hypothesize that, in the context of COVID-19, the SCs may be beneficial in patients with CT scans thoracic images suggestive of DAD either at the exudative phase or at the pulmonary organization phase.
The invention discloses a targeted liposome mediated by the ligand molecule with biological affinity, and a preparation as well as the application thereof. The targeted liposome of antitumor drug prepared by the invention has little toxicity, good tolerance for patients and enhanced water-solubility and stability. And the invention also discloses the processing technique of the preparation. Freeze-dry liposome consists of natural or synthetic phospholipid, charged phospholipid, target material, antitumor drugs, buffer solution and freeze-drying protective agent. The processing technique comprises the procedures of the preparation of phospholipid membrane of the antitumor drug, the homogenization of the liposome, the addition of the freeze-drying protective agent, volume metering, sterilizing, split charging, freeze-drying and storage, etc. The liposome is kept under room temperature for 12 months with good stability. The entrapment rate of the liposome is over 90 percent. The granule diameter of the liposome is within 50 to 300mm. The liposome has little toxic and side effects and simple technique, thus facilitating the commercial process of the liposome.
BACKGROUND: Germline breast cancer susceptibility gene (gBRCA) mutation in patients with pancreatic cancer (PC) is not common in clinical practice. Therefore, factors that efficiently show gBRCA mutations and the real-world outcomes of olaparib maintenance therapy have not been fully established. In the present study, we clarified the indicators for the effective detection of gBRCA mutation and the efficacy and safety of olaparib as maintenance therapy.
METHODS: We retrospectively analyzed 84 patients with PC who underwent gBRCA testing (BRACAnalysis, Myriad Genetics, Salt Lake City, UT, USA) at our institute between January 2021 and March 2022. For each patient, clinical data were extracted from medical records.
RESULTS: The median patient age was 64 y (29-85 y), and 41 patients (48.8%) were male. The gBRCA mutations were identified in 10 (11.9%) patients; two patients had BRCA1 mutation and eight had BRCA2 mutation. All patients with gBRCA mutation had a family history of any cancer, and eight of them had a family history of Hereditary Breast and Ovarian Cancer syndrome (HBOC)-related cancer. The gBRCA mutation rate was higher for patients with PC with a family history of HBOC-related cancer compared to that in patients with PC having a family history of other cancers and no family history of cancer (22.9% vs. 4.1%; P = 0.014). In our study, eight out of 10 patients with gBRCA-positive PC received olaparib after platinum-based chemotherapy. The best responses to platinum-based chemotherapy included a complete response in one patient (12.5%) and a partial response in seven patients (87.5%). The median duration of treatment with platinum-based chemotherapy plus olaparib was 17.5 months (8-87 months), and the duration of treatment with olaparib maintenance therapy was 11 months (1-30 months). During olaparib maintenance therapy, three patients showed no disease progression. One of these three patients underwent conversion surgery after receiving olaparib for 12 months.
CONCLUSIONS: The gBRCA testing should be considered proactively, especially in patients with PC with a family history of HBOC-related cancer.
A compsn. for the repair of depressed cutaneous scars comprises fibrin stabiliser(s) (I) and plasma (II) in an amt. to provide sufficient fibrin within a cavity formed under the scar and the fibrin stabiliser being present in an amt. to maintain the fibrin in the cavity and thereby cause build-up of collagen. The build-up of collagen results in the permanent elevation of the depression to produce a more continuous skin surface that improves the cosmetic appearance of the patient. Pref. compsns. comprise 20-50 mg of absorbable gelatin sponge, 12.5-75 mg of aminocaproic acid and 0.3-5cc of plasma.
A system and method are provided for reshaping the surface of a resilient transparent material such as a cornea. In the system, a laser unit generates a femto-second laser beam to deliver focused energy inside the material. Specifically, the energy is focused over a defined spot pattern to weaken the material. Further, the system includes a contact element that forms a contour surface. In order to reshape the material, the system provides for holding the contour surface of the contact element against the surface of the weakened material. After holding the contour surface against the material for a pre-determined time duration, the surface of the material is reshaped with a desired configuration that substantially mimics the contour surface of the contact element.
The objective of this evaluation is to collect and compare short-term factors related to the morbidity of approach using traditional posterior-approach interbody fusion techniques and a less invasive exposure for the same procedure. Perioperative measures and early outcomes will be documented to demonstrate differences in procedural requirements, safety, and early recovery. A total of 100 subjects will be consecutively enrolled in this prospective study from as many as 8 centers. Patients who, in the surgeon investigator's opinion, require instrumented lumbar interbody fusion and have consented to PLIF surgery for their conditions will be included. The following eligibility criteria are designed to identify existing clinic patients for whom study under this protocol is considered appropriate. All subjects must meet the inclusion/exclusion criteria in order to be considered for enrollment.
High calorie solutions of low molecular weight glucose polymer mixtures useful for intravenous administration, preferably via a peripheral vein, are disclosed. Methods of preparing the solutions and their preferred rate of infusion at less than 5 mg./min./kg. of patient body weight are also disclosed. The solutions can be isotonic to human blood at 20-50% W/V as the glucose polymer mixtures have an average degree of polymerization ranging from 4 to 10. At the preferred rate of infusion high utilization of the glucose polymers infused occurs in human patients, including diabetics. The utilization can be further enhanced by concomitant injections of insulin. The solutions can be administered concomitantly with amino acids, lipid emulsions, vitamins and electrolytes.
Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose, orally for 24 weeks. The eligible participants may enter the extension phase and will receive JNJ-56136379 along with NA (ETV or TDF) from Week 24 to Week 48.
To provide an awakening method which allows for maintaining or the like an awakened state of a person without making the person uncomfortable.SOLUTION: The present invention is an awakening method by emission of vaporized α-pinene (fragrance ingredient). It is preferable to emit α-pinene within a range where odor intensity based on a 6-grades odor intensity measurement method is 3 or less (1 to 2 in particular). More specifically, it is preferable to present α-pinene so as to make concentration become 0.01 to 7 ppm. In such a case, presenting α-pinene only intermittently is sufficient, and consumption of α-pinene can be thus suppressed. For example, α-pinene may be emitted for 3 to 30 seconds by every 10 to 60 seconds. α-pinene may be emitted according to an awakened level of a person (drowsiness rating by index of gradual eyeball movement, etc.). Particularly, when a method of the present invention is performed on a driver or the like of a vehicle, drowsy driving or the like can be suppressed.SELECTED DRAWING: Figure 1
The invention provides talcum powder. The talcum powder is prepared by using silkworm chrysalis protein peptide as the main raw material, and adding corn starch and other auxiliary materials. The invention also discloses a preparation method for the silkworm chrysalis protein peptide talcum powder. The preparation method comprises steps of stirring, smashing, baking, packaging, sterilizing, and the like. The product of the talcum powder adopts natural components, and is fine in powder and nonirritating to human skin. The product of the talcum powder is capable of lubricating skin, absorbing moisture and permeating air, and improving physical immunity.
PURPOSE:To provide a new derivative effective in treating leukemia, tumors such as osteosarcoma, breast cancer and ovarioncus and an anticancer agent containing the derivative as an active ingredient. CONSTITUTION:This-derivative has a formula I (X= is CH2=, formula II or O=; R is H or a lower alkyl; the mark-represents cis or trans to bond of CH2 group whose bond is adjacent; a chain line is a single bond or a double bond). This anticancer agent is obtained by blending the derivative with a diluent or a carrier. Preferred example of the derivative is a derivative of formula III. The derivative is obtained by lactonizing, e.g. 6-methyl-3-cyclohexene-1- carboxylic acid, subjecting the resultant compound to decomposition, reduction, protection, acetylation and deprotection to afford an intermediate of formula IV, subjecting the intermediate of formula IV to ozone oxidation and Wittig reaction to give an intermediate of formula V, cyclizing the intermediate of formula V by conjugaion-addition reaction using an acid catalyst, hydrolyzing the cyclized compound, introducing a double bond into the compound to afford an intermediate of formula VI and further, reacting the intermediate with a silyl ether and palladium acetate.
OBJECTIVES: I. Evaluate the early efficacy and toxicity profile of high-dose cisplatin, etoposide, bleomycin, and amifostine in children with newly diagnosed, high-risk malignant, extragonadal germ cell tumors. II. Determine whether the use of amifostine can reduce the hematologic and nonhematologic toxic effects of this combination chemotherapy in these patients when compared to similar patients treated on POG-9049/CCG-8881 with the same combination chemotherapy. III. Determine the response rate of patients treated with this regimen.

OUTLINE: Patients undergo surgical biopsy or resection. Patients then receive bleomycin IV over 10 minutes on day 1 and etoposide IV over 1 hour, amifostine IV over 15 minutes, and cisplatin IV over 1 hour on days 1-5. Treatment repeats every 3-4 weeks for 4 courses in the absence of unacceptable toxicity or disease progression. Patients who have no disease after 4 courses of chemotherapy receive no further treatment. Patients who have residual disease undergo second-look surgery. After surgery, patients who still have active tumor receive 2 additional courses of chemotherapy. Those patients who still have tumor after the 2 additional courses may have a third surgery. Patients are followed every month for 6 months, every 2 months for 6 months, every 6 months for 1 year, and then annually thereafter until death.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 1.39 years.
NFE2-related factor 2 (NRF2) is a master transcription factor (TF) that coordinates key cellular homeostatic processes including antioxidative responses, autophagy, proteostasis, and metabolism. The emerging evidence underscores its significant role in modulating inflammatory and immune processes. This chapter delves into the role of NRF2 in myeloid cell differentiation and function and its implication in myeloid cell-driven diseases. In macrophages, NRF2 modulates cytokine production, phagocytosis, pathogen clearance, and metabolic adaptations. In dendritic cells (DCs), it affects maturation, cytokine production, and antigen presentation capabilities, while in neutrophils, NRF2 is involved in activation, migration, cytokine production, and NETosis. The discussion extends to how NRF2's regulatory actions pertain to a wide array of diseases, such as sepsis, various infectious diseases, cancer, wound healing, atherosclerosis, hemolytic conditions, pulmonary disorders, hemorrhagic events, and autoimmune diseases. The activation of NRF2 typically reduces inflammation, thereby modifying disease outcomes. This highlights the therapeutic potential of NRF2 modulation in treating myeloid cell-driven pathologies.
Tissue cooling (cryotherapy treatment) is a long-standing pain therapy for the treatment of acute injuries and during rehabilitation. It is used in addition to other treatments . The main purpose of cryotherapy is to cool the tissue temperature and is used in the clinic in the form of various cryotherapy modalities such as whole body cryotherapy, cold spray, cryotherapy clamps, frozen peas, cold water immersion, ice and cold packs . The first physiological response of cooling is a decrease in tissue temperature . Studies have shown that local cold application causes increased resistance to movement . Although it has been reported in animal studies conducted in vitro that muscle tissue shows high resistance to stretching after cooling down , only one study evaluating direct mechanical responses to muscles in human studies There. In this study carried out by Mustalampi et al., Parameter measurements indicating the mechanical properties of the muscle immediately after applying the cold pack applied locally to the quadriceps muscle for 20 minutes and after 15 minutes. As a result of the study, the muscle has become stiffer, less elastic in terms of mechanical properties and it has been shown that these changes do not completely recover after 15 minutes. It was also stated that careful warm-up should be recommended after cooling to normalize the mechanical properties of the muscle and prevent injury .

Also known as cold spray, vikocoolant spray is a form of cryotherapy used in sports medicine, athletic training and rehabilitation environments and is widely used in the world . Especially in field medicine, it is frequently used as the first treatment of sports injuries. However, as is often done, returning to the game and competition with the help of the emerging analgesia is inconvenient in terms of the treatment of injury . However, it is still used frequently due to ease of application. The use of cold spray as a therapeutic method is of particular interest, as it is typically applied for a much shorter time than other cryotherapy modes . It has been shown in the literature that local cold application can cause increased resistance to movement and it is reported that it can change the mechanical properties of the muscle in a short time. However, the effect of cold spray application on the mechanical properties of the muscle is unknown. Therefore, in the current study proposal, the investigators aim to investigate the acute effect of cold spray application on the mechanical properties of the quadriceps muscle in athletes.
PURPOSE:To obtain a cosmetic for covering wrinkles, having good feeling in use, excellent covering degree of fine wrinkles and durability of make-up, further a transparent feeling and high safety, comprising a solid fat, liquid oil and extender pigment power in a specific ratio. CONSTITUTION:A solid fat (e.g. microcrystalline wax or stearic acid), a liquid oil (e.g. liquid paraffin or jojoba oil) and extender pigment powder are contained as essential components and properly blended with an auxiliary film-forming agent (e.g. polymer silicon), a humectant, an antiseptic, a colorant, a medicinal component, a volatile oil agent, purified water and prepared under heating while stirring to give the objective substance. The blending ratio of the solid fat and the liquid oil is (2:1)-(99:1) by weight and the blending ratio of sum of both the solid fat and the liquid oil and the extender pigment power is (2:1)-(1:4).
Novel KCNMA1 variants, encoding the BK K+ channel, are associated with a debilitating dyskinesia and epilepsy syndrome. Neurodevelopmental delay, cognitive disability, and brain and structural malformations are also diagnosed at lower incidence. More than half of affected individuals present with a rare negative episodic motor disorder, paroxysmal nonkinesigenic dyskinesia (PNKD3). The mechanistic relationship of PNKD3 to epilepsy and the broader spectrum of KCNMA1-associated symptomology is unknown. This review summarizes patient-associated KCNMA1 variants within the BK channel structure, functional classifications, genotype-phenotype associations, disease models, and treatment. Patient and transgenic animal data suggest delineation of gain-of-function (GOF) and loss-of-function KCNMA1 neurogenetic disease, validating two heterozygous alleles encoding GOF BK channels (D434G and N999S) as causing seizure and PNKD3. This discovery led to a variant-defined therapeutic approach for PNKD3, providing initial insight into the neurological basis. A comprehensive clinical definition of monogenic KCNMA1-linked disease and the neuronal mechanisms currently remain priorities for continued investigation.
Subjects will receive all three treatments in a crossover fashion according to the randomized sequence. The treatments were as follows: single oral administration of GP681 at 40 mg on day 1 in the fasted state; single oral administration of oseltamivir at 75 mg on day 1 and day 5in the fasted state, followed by repeated twice-daily administration of oseltamivir at 75 mg until day 5 after each meal; co-administration of GP681 at 40 mg and oseltamivir at 75 mg simultaneously on day 1 in the fasted state, followed by repeated twice-daily administration of oseltamivir at 75 mg until day5 after each meal. There was an at least 21-day washout interval between each treatment.